CN100502945C - Vegf受体融合蛋白在治疗眼睛疾病中的应用 - Google Patents

Vegf受体融合蛋白在治疗眼睛疾病中的应用 Download PDF

Info

Publication number
CN100502945C
CN100502945C CNB2006100662572A CN200610066257A CN100502945C CN 100502945 C CN100502945 C CN 100502945C CN B2006100662572 A CNB2006100662572 A CN B2006100662572A CN 200610066257 A CN200610066257 A CN 200610066257A CN 100502945 C CN100502945 C CN 100502945C
Authority
CN
China
Prior art keywords
preparation
fusion protein
sequence
application according
vegf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CNB2006100662572A
Other languages
English (en)
Chinese (zh)
Other versions
CN1915427A (zh
Inventor
俞德超
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chengdu Kanghong Biotechnologies Co Ltd
Original Assignee
Chengdu Kanghong Biotechnologies Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chengdu Kanghong Biotechnologies Co Ltd filed Critical Chengdu Kanghong Biotechnologies Co Ltd
Priority to CNB2006100662572A priority Critical patent/CN100502945C/zh
Publication of CN1915427A publication Critical patent/CN1915427A/zh
Priority to CA002647142A priority patent/CA2647142A1/en
Priority to RU2008136655/13A priority patent/RU2008136655A/ru
Priority to EP07720595A priority patent/EP2000483A4/en
Priority to PCT/CN2007/001021 priority patent/WO2007112675A1/zh
Priority to BRPI0710223-2A priority patent/BRPI0710223A2/pt
Priority to KR1020087025464A priority patent/KR20090010030A/ko
Priority to JP2009501824A priority patent/JP2009531036A/ja
Priority to AU2007234272A priority patent/AU2007234272A1/en
Priority to US12/241,017 priority patent/US20090264358A1/en
Priority to US12/457,478 priority patent/US8216575B2/en
Application granted granted Critical
Publication of CN100502945C publication Critical patent/CN100502945C/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CNB2006100662572A 2006-03-31 2006-03-31 Vegf受体融合蛋白在治疗眼睛疾病中的应用 Active CN100502945C (zh)

Priority Applications (11)

Application Number Priority Date Filing Date Title
CNB2006100662572A CN100502945C (zh) 2006-03-31 2006-03-31 Vegf受体融合蛋白在治疗眼睛疾病中的应用
KR1020087025464A KR20090010030A (ko) 2006-03-31 2007-03-29 Ｖｅｇｆ 수용체 융합 단백질 및 그의 용도
AU2007234272A AU2007234272A1 (en) 2006-03-31 2007-03-29 VEGF receptor fusion protein and use thereof
EP07720595A EP2000483A4 (en) 2006-03-31 2007-03-29 VEGF RECEPTOR FUSION PROTEIN AND APPLICATION THEREOF
PCT/CN2007/001021 WO2007112675A1 (fr) 2006-03-31 2007-03-29 Protéine de fusion du récepteur du vegf et son utilisation
BRPI0710223-2A BRPI0710223A2 (pt) 2006-03-31 2007-03-29 proteìnas de fusão de receptor de vegf e seu uso
CA002647142A CA2647142A1 (en) 2006-03-31 2007-03-29 Vegf receptor fusion protein and use thereof
JP2009501824A JP2009531036A (ja) 2006-03-31 2007-03-29 Ｖｅｇｆ受容体融合タンパク質およびそれらの使用
RU2008136655/13A RU2008136655A (ru) 2006-03-31 2007-03-29 Гибридные белки рецептора vegf, их фармацевтические композиции и терапевтическое применение при заболеваниях глаз
US12/241,017 US20090264358A1 (en) 2006-03-31 2008-09-29 Vegf receptor fusion proteins, their pharmaceutical compositions and therapeutic applications for the eye diseases
US12/457,478 US8216575B2 (en) 2006-03-31 2009-06-11 Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB2006100662572A CN100502945C (zh) 2006-03-31 2006-03-31 Vegf受体融合蛋白在治疗眼睛疾病中的应用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNB2008101608428A Division CN100567325C (zh) 2006-03-31 2006-03-31 Vegf受体融合蛋白及其在制备治疗眼睛疾病的药物中的应用

Publications (2)

Publication Number Publication Date
CN1915427A CN1915427A (zh) 2007-02-21
CN100502945C true CN100502945C (zh) 2009-06-24

Family

ID=37736587

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2006100662572A Active CN100502945C (zh) 2006-03-31 2006-03-31 Vegf受体融合蛋白在治疗眼睛疾病中的应用

Country Status (10)

Country Link
US (1) US20090264358A1 (enExample)
EP (1) EP2000483A4 (enExample)
JP (1) JP2009531036A (enExample)
KR (1) KR20090010030A (enExample)
CN (1) CN100502945C (enExample)
AU (1) AU2007234272A1 (enExample)
BR (1) BRPI0710223A2 (enExample)
CA (1) CA2647142A1 (enExample)
RU (1) RU2008136655A (enExample)
WO (1) WO2007112675A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11253572B2 (en) 2011-01-13 2022-02-22 Regeneron Pharmaceuticals, Inc. Use of a VEGF antagonist to treat angiogenic eye disorders
US11732024B2 (en) 2006-06-16 2023-08-22 Regeneron Pharmaceuticals, Inc. VEGF antagonist formulations suitable for intravitreal administration
US11806398B2 (en) 2005-03-25 2023-11-07 Regeneron Pharmaceuticals, Inc. Citrate buffered VEGF antagonist formulations
US12103960B2 (en) 2020-05-08 2024-10-01 Regeneron Pharmaceuticals, Inc. VEGF traps and mini-traps and methods for treating ocular disorders and cancer
US12280093B2 (en) 2017-11-30 2025-04-22 Regenron Pharmaceuticals, Inc. Use of a VEGF receptor-based fusion protein antagonist to treat nonproliferative diabetic retinopathy

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101279092B (zh) * 2007-04-02 2010-10-27 成都康弘生物科技有限公司 Vegf受体融合蛋白在制备治疗与血管生成有关的疾病中的应用
CN101721699B (zh) * 2008-10-13 2012-11-07 成都康弘生物科技有限公司 Vegf受体融合蛋白在制备治疗伴随vegf升高的炎症反应的药物中的应用
KR101248912B1 (ko) * 2009-12-31 2013-03-29 한양대학교 산학협력단 항혈관신생 활성을 가지는 재조합 아데노바이러스
CN102233132B (zh) * 2010-04-28 2013-10-23 成都康弘生物科技有限公司 Vegf受体融合蛋白在制备抑制眼表新生血管生长的药物中的应用
CN102380096B (zh) * 2010-08-31 2014-04-30 成都康弘生物科技有限公司 一种含有抑制血管增生的融合蛋白的药物组合物及用途
CN103816115B (zh) * 2010-08-31 2017-06-27 成都康弘生物科技有限公司 一种含有抑制血管增生的融合蛋白的药物组合物及用途
KR102049990B1 (ko) 2013-03-28 2019-12-03 삼성전자주식회사 c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
JP6631865B2 (ja) * 2014-08-11 2020-01-15 日本化薬株式会社 ＴＧＦβ阻害機能を持つキメラタンパク質
EP3985023A1 (en) 2014-12-11 2022-04-20 Bayer Healthcare LLC Treatment of age related macular degeneration with a small active choroidal neovascularization lesion
WO2017046140A1 (en) 2015-09-18 2017-03-23 Bayer Pharma Aktiengesellschaft Treatment regimens for dr and rvo in dependence of the extent of retinal ischemia
MX2020009152A (es) 2018-03-02 2020-11-09 Kodiak Sciences Inc Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
PT4364724T (pt) 2018-05-10 2025-12-16 Regeneron Pharma Formulações contendo uma proteína de fusão do recetor do vegf de concentração elevada
EP3812402B1 (en) * 2018-12-07 2024-11-20 RemeGen Co., Ltd. Bifunctional angiogenesis inhibitor and use thereof
CN115335529A (zh) * 2019-11-26 2022-11-11 马萨诸塞大学 用于递送kh902(康柏西普)的重组腺相关病毒及其用途
EP3906303A1 (en) 2019-12-06 2021-11-10 Regeneron Pharmaceuticals, Inc. Anti-vegf protein compositions and methods for producing the same
ES3041647T3 (en) 2021-05-17 2025-11-13 Regeneron Pharma Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders
IL315347A (en) 2022-03-15 2024-11-01 Regeneron Pharma Prolonged high-dose VEGF antagonist regimens for the treatment of angiogenic ocular disorders
CN119136823A (zh) 2022-03-15 2024-12-13 瑞泽恩制药公司 用于治疗血管生成性眼病的延长的高剂量vegf拮抗剂方案
KR20250065646A (ko) 2022-09-16 2025-05-13 치루 파머수티컬 컴퍼니 리미티드 안정적인 고농도 자가완충식 약물 조성물
WO2024263995A1 (en) 2023-06-23 2024-12-26 Regeneron Pharmaceuticals, Inc. Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders
WO2025140553A1 (zh) * 2023-12-27 2025-07-03 成都康弘生物科技有限公司 一种含有抗vegf的融合蛋白的药物组合物
WO2025217334A1 (en) 2024-04-09 2025-10-16 Regeneron Pharmaceuticals, Inc. Low concentration vegf receptor fusion protein containing formulations
CN118108862B (zh) * 2024-04-29 2024-08-09 上海鼎新基因科技有限公司 抗血管新生的融合蛋白及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005027973A2 (en) * 2003-09-23 2005-03-31 Novartis Ag Combinations of a vegf receptor inhibitor with other therapeutic agents
CN1706867A (zh) * 2004-06-08 2005-12-14 成都康弘科技实业（集团）有限公司 抑制血管新生的融合蛋白质及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7087411B2 (en) * 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
CN100523187C (zh) * 1999-06-08 2009-08-05 里珍纳龙药品有限公司 具有改善的药物动力学特性的修饰嵌合多肽
EP1767546B1 (en) * 2004-06-08 2012-03-07 Chengdu Kanghong Biotechnologies Co., Ltd. Angiogenesis-inhibiting chimeric protein and the use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005027973A2 (en) * 2003-09-23 2005-03-31 Novartis Ag Combinations of a vegf receptor inhibitor with other therapeutic agents
CN1706867A (zh) * 2004-06-08 2005-12-14 成都康弘科技实业（集团）有限公司 抑制血管新生的融合蛋白质及其用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
血管内皮生长因子及其受体与眼内新生血管性疾病. 赵世红综述，何守志审校.眼科研究，第21卷第1期. 2003 *
血管内皮生长因子受体的结构与功能. 张曼等.生物化学与生物物理进展，第24卷第1期. 1997 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11806398B2 (en) 2005-03-25 2023-11-07 Regeneron Pharmaceuticals, Inc. Citrate buffered VEGF antagonist formulations
US11732024B2 (en) 2006-06-16 2023-08-22 Regeneron Pharmaceuticals, Inc. VEGF antagonist formulations suitable for intravitreal administration
US12331099B2 (en) 2006-06-16 2025-06-17 Regeneron Pharmaceuticals, Inc. VEGF antagonist formulations suitable for intravitreal administration
US11253572B2 (en) 2011-01-13 2022-02-22 Regeneron Pharmaceuticals, Inc. Use of a VEGF antagonist to treat angiogenic eye disorders
US11559564B2 (en) 2011-01-13 2023-01-24 Regeneron Pharmaceuticals, Inc. Use of a VEGF antagonist to treat angiogenic eye disorders
US11707506B2 (en) 2011-01-13 2023-07-25 Regeneren Pharmaceuticals, Inc. Use of a VEGF antagonist to treat angiogenic eye disorders
US11730794B2 (en) 2011-01-13 2023-08-22 Regeneron Pharmaceuticals, Inc. Use of a VEGF antagonist to treat angiogenic eye disorders
US11975045B2 (en) 2011-01-13 2024-05-07 Regeneron Pharmaceuticals, Inc. Use of a VEGF antagonist to treat angiogenic eye disorders
US11986511B2 (en) 2011-01-13 2024-05-21 Regeneron Pharmaceuticals, Inc. Use of a VEGF antagonist to treat angiogenic eye disorders
US12268730B2 (en) 2011-01-13 2025-04-08 Regeneron Pharmaceuticals, Inc. Use of a VEGF antagonist to treat angiogenic eye disorders
US12280093B2 (en) 2017-11-30 2025-04-22 Regenron Pharmaceuticals, Inc. Use of a VEGF receptor-based fusion protein antagonist to treat nonproliferative diabetic retinopathy
US12103960B2 (en) 2020-05-08 2024-10-01 Regeneron Pharmaceuticals, Inc. VEGF traps and mini-traps and methods for treating ocular disorders and cancer

Also Published As

Publication number Publication date
WO2007112675A1 (fr) 2007-10-11
CN1915427A (zh) 2007-02-21
WO2007112675A8 (fr) 2009-07-09
US20090264358A1 (en) 2009-10-22
BRPI0710223A2 (pt) 2011-08-02
CA2647142A1 (en) 2007-10-11
AU2007234272A1 (en) 2007-10-11
RU2008136655A (ru) 2010-05-10
EP2000483A2 (en) 2008-12-10
EP2000483A9 (en) 2009-03-18
JP2009531036A (ja) 2009-09-03
KR20090010030A (ko) 2009-01-28
EP2000483A4 (en) 2009-10-28

Similar Documents

Publication Publication Date Title
CN100502945C (zh) Vegf受体融合蛋白在治疗眼睛疾病中的应用
US20250152669A1 (en) Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders
CN116585466A (zh) 含有高浓度vegf受体融合蛋白的制剂
CN100567325C (zh) Vegf受体融合蛋白及其在制备治疗眼睛疾病的药物中的应用
CN104204218A (zh) 生长分化因子15 (gdf-15)多肽
US20230414788A1 (en) Formulations for suprachoroidal administration such as gel formulations
RU2426745C2 (ru) Рекомбинантный химерный белок фактора ингибирования нейтрофилов и гиругена и содержащая его фармацевтическая композиция
CN111068071A (zh) 基因治疗Leber遗传学视神经病变
CN100484957C (zh) 胸腺素β4衍生物及其应用
AU2010213591B2 (en) Compositions and methods for minimally-invasive systemic delivery of proteins including TGF-beta superfamily members
EP4429693B1 (en) Monomeric annexin a5 for use in the treatment of macular oedema or retinal vein occlusion
US20240228566A1 (en) Compositions and methods for vascular protection after myocardial ischemia
CN116635004A (zh) 用于脉络膜上施用的制剂如凝胶制剂
AU2023250660A1 (en) Pharmaceutical composition comprising a recombinant adenoassociated virus vector with an expression cassette encoding a transgene for suprachoroidal administration
WO2024133908A1 (en) Stable pharmaceutical compositions comprising romiplostim
HK40115628A (en) Monomeric annexin a5 for use in the treatment of macular oedema or retinal vein occlusion
HK40115628B (en) Monomeric annexin a5 for use in the treatment of macular oedema or retinal vein occlusion
CA3253955A1 (en) ANNEXIN A5 MONOMER FOR USE IN THE TREATMENT OF MACULAR EDEMA OR RETINAL VEIN OCCUSION
AU2013206500A1 (en) Compositions and methods for minimally-invasive systemic delivery of proteins including TGF-beta superfamily members

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CI01 Publication of corrected invention patent application

Correction item: Applicant address

Correct: No. 36, Shu Shu West Road, Chengdu, Sichuan, Jinniu District

False: No. 36, Shu Shu West Road, Chengdu, Heilongjiang, Jinniu District

Number: 08

Volume: 23

CI02 Correction of invention patent application

Correction item: Applicant address

Correct: No. 36, Shu Shu West Road, Chengdu, Sichuan, Jinniu District

False: No. 36, Shu Shu West Road, Chengdu, Heilongjiang, Jinniu District

Number: 08

Page: The title page

Volume: 23

ERR Gazette correction

Free format text: CORRECT: APPLICANT ADDRESS; FROM: * ROAD, NO. 36, SHU ROAD(WEST), JINNIU DISTRICT, CHENGDU CITY, HEILONGJIANG PROVINCE TO: * ROAD, NO. 36, SHU ROAD(WEST), JINNIU DISTRICT, CHENGDU CITY, SICHUAN PROVINCE

C14 Grant of patent or utility model
GR01 Patent grant